Diopter Technologies Advances Ocular Disease Treatment with Dissolving Contact Lens
Diopter Technologies has completed early clinical studies for a dissolving amniotic membrane biopolymer contact lens, offering a novel approach to treating ocular surface diseases by delivering growth factors directly to the eye.
Diopter Technologies has announced the completion of early clinical studies for its innovative dissolving amniotic membrane and biopolymer contact lens, a groundbreaking therapeutic device aimed at treating various ocular surface diseases. This device represents a significant advancement in the field, offering a solution that not only protects the eye but actively promotes healing by releasing growth factors from amniotic-derived materials. The lens is designed to dissolve completely within 48-72 hours, eliminating the need for clinical removal and reducing the risk of disrupting healing tissues.
The clinical study results have shown promising outcomes, with no adverse events reported and an increase in patient comfort compared to traditional silicon hydrogel lenses over a 48-hour wear period. Chris Adams, CEO of Diopter Technologies, highlighted the device's ability to transform ocular surface rehabilitation from passive coverage to intelligent tissue remodeling, thanks to its unique combination of amniotic and resorbable biomaterials.
With the device currently undergoing clinical studies for multiple indications, including chemical/thermal injury recovery, post-refractive surgery care, and chronic dry eye management, Diopter Technologies is poised to address significant market opportunities. The company plans to launch the product in Q1 2026, following the completion of ongoing human trials and submission of an FDA 510K application. This development marks a strategic expansion of Diopter's ocular drug delivery portfolio, further establishing its position as a pioneer in bio-integrated solutions for ophthalmology.